| Status: Under consideration by AWMSG Scrutiny Panel | |
Neoadjuvant followed by adjuvant treatment of stage IIIB – IIID or oligometastatic stage IV melanoma in adults (off label). |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 100 mg/4 ml concentrate for solution for infusion |
| Reference number | 10900 |
| Indication | As above |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 06/08/2026 |